Clinical Trials Logo

Clinical Trial Summary

The phase 2 study will evaluate the safety, tolerability and efficacy of HLD100 at steady state (following up to 5 weeks of treatment) in children using an outpatient, single-center, open-label, flexible dose-escalation study design.


Clinical Trial Description

This dose-escalation study will examine HLD100 in 24 subjects. The subjects (n=24) will be tested with HLD100 in ascending doses from 10mg up to 40mg. This study will be divided into several phases: Screening, Active Treatment and Follow-Up. All visits have a 2 day window to allow for scheduling. ;


Study Design


Related Conditions & MeSH terms

  • Attention Deficit Disorder with Hyperactivity
  • Attention-Deficit Hyperactivity Disorder (ADHD)

NCT number NCT02884544
Study type Interventional
Source Ironshore Pharmaceuticals and Development, Inc
Contact
Status Completed
Phase Phase 2
Start date August 2016
Completion date December 27, 2016

See also
  Status Clinical Trial Phase
Completed NCT01430767 - Measuring Adherence to Medication for Depression and Attention-deficit Hyperactivity Disorder N/A
Completed NCT03231800 - A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years Old With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. Phase 3
Completed NCT02286817 - Phase I Single Dose, Open-Label Pharmacokinetic Study and Single-Blind, Placebo-Controlled Dose Escalation Study of NFC-1 in Adolescents With Attention-Deficit Hyperactivity Disorder Phase 1
Completed NCT02699086 - A Study of PDC-1421 Treatment in Adult Patients With Attention-Deficit Hyperactivity Disorder (ADHD) Phase 2
Suspended NCT05202327 - PDC-1421 Treatment in Adult Patients With ADHD Phase 2
Completed NCT02734693 - A Study to Evaluate the Efficacy and Safety of Dasotraline in Children 6 to 12 Years of Age With Attention-Deficit Hyperactivity Disorder (ADHD) in a Simulated Classroom Setting. Phase 3